Sharekhan has given Buy recommendation for Lupin with a target price of Rs. 1350 in its research report issued on Jan 29, 2021

Sharekhan’s research report on Lupin

Q3FY2021 was a healthy quarter for the company and adjusting for one offs the earnings are ahead of estimates. US business is on a strong footing to grow, backed by better-than-expected ramp up of its respiratory product, gAlbuterol and new launches, while India business is expected to improve backed by strong growth in chronics while improving patient footfalls point at pick up in the acute therapy. Focus on cost-control measures and rationalization coupled with benefits of operating leverage and high share of new launches to drive OPM expansion.

Outlook

We retain Buy recommendation on Lupin Limited (Lupin) with an unchanged PT of RS 1350.

For all recommendations report, click here

Leave a Reply

Your email address will not be published. Required fields are marked *